


The burden of antimicrobial resistance (AMR) in the United States of America

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **40,000 lives** have been lost each year since 1990 in the United States of America due to AMR.
- In 2021, there were an estimated **39,000 UI (34,600-43,400)** deaths attributable to AMR and **165,000 UI (149,000-182,000)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to macrolides, *Staphylococcus aureus* resistant to methicillin and *Enterococcus faecium* resistant to vancomycin.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For the United States, a 10% reduction means to decrease the number of deaths associated with AMR to **148,000**, but currently the trend for this country could reach up to **204,000 UI [166,000-233,000]** AMR-associated deaths in 2030.

AMR in the United States of America

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in the United States of America between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In the United States of America in 2021, there were an estimated **39,000 UI (34,600-43,400)** deaths attributable to AMR and **165,000 UI (149,000-182,000)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **the United States of America has the 34th lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Staphylococcus aureus 78,600 UI (70,800-86,300) ↑	Staphylococcus aureus 60,000 UI (52,800-67,300) ↑	Staphylococcus aureus 16,300 UI (13,700-18,900) ↑
	Escherichia coli 48,200 UI (43,200-53,200) ↑	Escherichia coli 32,500 UI (28,100-36,900) ↑	Escherichia coli 5,840 UI (4,700-6,990) ↑
	Pseudomonas aeruginosa 28,700 UI (26,000-31,400) ↑	Pseudomonas aeruginosa 15,000 UI (13,500-16,400) ↑	Pseudomonas aeruginosa 3,850 UI (3,230-4,470) ↑
	Klebsiella pneumoniae 22,600 UI (20,400-24,800) ↑	Streptococcus pneumoniae 12,000 UI (10,700-13,200) ↓	Acinetobacter baumannii 2,790 UI (2,480-3,100) ↓
	Streptococcus pneumoniae 22,300 UI (20,200-24,400) ↓	Klebsiella pneumoniae 8,840 UI (7,960-9,730) ↑	Enterococcus faecium 2,500 UI (2,210-2,800) ↑
	Group A Streptococcus 10,600 UI (9,350-11,800) ↑	Enterococcus faecium 7,930 UI (7,200-8,670) ↑	Klebsiella pneumoniae 2,070 UI (1,780-2,350) ↑
	Enterococcus faecalis 9,720 UI (8,790-10,700) ↑	Acinetobacter baumannii 7,070 UI (6,400-7,750) ↓	Streptococcus pneumoniae 2,040 UI (1,690-2,400) ↓
	Acinetobacter baumannii 9,040 UI (8,230-9,840) ↓	Proteus spp. 3,990 UI (3,470-4,510) ↑	Enterobacter spp. 879 UI (773-986) ↓
	Enterococcus faecium 8,460 UI (7,680-9,240) ↑	Enterobacter spp. 3,320 UI (2,990-3,660) ↓	Enterococcus faecalis 608 UI (470-746) ↑
	Proteus spp. 8,010 UI (7,120-8,900) ↑	Enterococcus faecalis 2,940 UI (2,640-3,240) ↓	Proteus spp. 579 UI (467-690) ↑

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (red), >5.0% (dark red),
 -3% to -1.5% (medium blue), 0% to 1.5% (orange), 3% to 5% (brown)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Staphylococcus aureus Methicillin 49,000 UI (38,900-59,100) ↑	Staphylococcus aureus Methicillin 11,900 UI (9,330-14,500) ↑
	Staphylococcus aureus Macrolides 48,800 UI (43,300-54,200) ↑	Enterococcus faecium Vancomycin 1,940 UI (1,660-2,220) ↑
	Staphylococcus aureus Fluoroquinolones 31,800 UI (28,100-35,600) ↑	Staphylococcus aureus Macrolides 1,900 UI (1,250-2,540) ↑
	Escherichia coli Aminopenicillin 27,500 UI (22,200-32,700) ↑	Staphylococcus aureus Fluoroquinolones 1,880 UI (845-2,920) ↑
	Escherichia coli Fluoroquinolones 18,500 UI (15,600-21,400) ↑	Pseudomonas aeruginosa Carbapenems 1,870 UI (1,300-2,440) ↑
	Escherichia coli TMP-SMX 14,400 UI (11,100-17,700) ↑	Escherichia coli Fluoroquinolones 1,410 UI (825-1,990) ↑
	Escherichia coli Beta-Lactam/Lactamase Inhib. 13,900 UI (11,500-16,400) ↑	Acinetobacter baumannii Carbapenems 1,370 UI (1,090-1,660) ↓
	Pseudomonas aeruginosa Fluoroquinolones 10,300 UI (9,110-11,600) ↑	Streptococcus pneumoniae Carbapenems 1,300 UI (967-1,630) ↓
	Pseudomonas aeruginosa Carbapenems 9,680 UI (8,440-10,900) ↑	Escherichia coli Aminopenicillin 1,280 UI (919-1,630) ↑
	Escherichia coli 3GC 9,170 UI (7,780-10,600) ↑	Pseudomonas aeruginosa Fluoroquinolones 1,070 UI (736-1,400) ↑

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (red), >5.0% (dark red),
 -3% to -1.5% (medium blue), 0% to 1.5% (orange), 3% to 5% (brown)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (158,000 UI (143,000-173,000)), lower respiratory infection (excl. COVID) (119,000 UI (105,000-133,000)), peritoneal and intra-abdominal infections (43,200 UI (38,800-47,600)), urinary tract infections and pyelonephritis (30,600 UI (26,600-34,600)) and infections of the skin and subcutaneous systems (18,200 UI (15,600-20,700)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In the United States of America, people aged 70+ saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that 70+ continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the 70+ was 108,000 UI (93,300-123,000), whereas the mortality rate per 100,000 was 281 UI (242-320).

Data sources for the United States of America

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for the United States of America by source type

Source type	Years	Sample size	Sample size units
Hospital discharge	1990-2021	225,107	Discharges
Microbial or laboratory data without outcome	1990-2021	21,209,700	Isolates
Microbial or laboratory data with outcome	2010-2021	14,052,132	Isolates
Literature studies	1990-2021	149,626	Cases/isolates/susceptibility tests
Single drug resistance profile data	1990-2021	2,007,635	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>